In this study, we found higher expression levels of the immune checkpoint molecules (CTLA-4, PD-1, PD-L1, etc.)in the low-risk group, indicating that these melanoma patients may have a more favorable response to ICIs. The gene discussed is CTLA4; the disease is melanoma.